These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34586227)

  • 1. Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab.
    Rentiya ZS; Ferraz DA; Hutnik R; Bae J; Machado CG; Mucciolli C; Motta AALD; Ribeiro LZ; Guan Z; Preti RC; Takahashi WY
    Arq Bras Oftalmol; 2022; 85(1):37-45. PubMed ID: 34586227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy.
    Barroso RMP; Messias K; Garcia DM; Cardillo JA; Scott IU; Messias A; Jorge R
    Arq Bras Oftalmol; 2020; 83(6):526-534. PubMed ID: 33470281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation.
    Cao G; Xu X; Wang C; Zhang S
    Eur J Ophthalmol; 2020 Jan; 30(1):34-39. PubMed ID: 30539668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    ; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
    JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy.
    Lucena CR; Ramos Filho JA; Messias AM; Silva JA; Almeida FP; Scott IU; Ribeiro JA; Jorge R
    Arq Bras Oftalmol; 2013; 76(1):18-20. PubMed ID: 23812521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
    Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
    Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study.
    Toscano L; Messias A; Messias K; de Cenço Lopes R; Ribeiro JAS; Scott IU; Jorge R
    Doc Ophthalmol; 2021 Dec; 143(3):313-322. PubMed ID: 34347216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
    Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
    Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
    Ebneter A; Wolf S; Zinkernagel MS
    Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
    JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
    Messias K; Barroso RM; Jorge R; Messias A
    Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.
    Messias A; Ramos Filho JA; Messias K; Almeida FP; Costa RA; Scott IU; Gekeler F; Jorge R
    Doc Ophthalmol; 2012 Jun; 124(3):225-36. PubMed ID: 22457045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
    Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
    Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.